{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:27:15Z","timestamp":1769066835753,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n People with severe mental illness (SMI) are two to three times more likely to be overweight and obese than the general population and this is associated with significant morbidity and premature mortality. Although lifestyle interventions can support people with SMI to lose weight, some are unable to make the necessary lifestyle changes or, despite making the changes, continue to gain weight.<\/jats:p>\n <\/jats:sec>\n Objective<\/jats:title>\n To assess the feasibility and acceptability of delivering a full-scale trial evaluating whether liraglutide 3.0\u2009mg, a once-daily injectable therapy, may be an effective treatment of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n Design: a single-centre, double-blind, randomised, placebo-controlled trial.<\/jats:p>\n Setting: mental health facilities within Southern Health NHS Trust.<\/jats:p>\n Participants: 60 adults with schizophrenia, schizoaffective or first-episode psychosis prescribed antipsychotic medication will be recruited. Participants will be overweight or obese, defined by their baseline BMI which will be:<\/jats:p>\n \u2022 BMI \u2265 30\u2009kg\/m2<\/jats:sup> or<\/jats:p>\n \u2022 BMI \u2265 27\u2009kg\/m2<\/jats:sup> to <\u200930\u2009kg\/m2<\/jats:sup> in the presence of at least one weight-related consequence.<\/jats:p>\n This is in concordance with the current EU licence for liraglutide (maximum dosage 3.0\u2009mg).<\/jats:p>\n Intervention: participants will be allocated in a 1:1 ratio using a computer-based randomisation programme to either once-daily subcutaneously administered liraglutide or placebo, titrated to 3.0\u2009mg daily, for 6\u2009months. All participants will receive standardised written information about healthy eating and exercise at their randomisation visit.<\/jats:p>\n Outcomes: the main aim of the study is to gather data on recruitment, consent, retention and adherence. Qualitative interviews with a purposive sub-sample of participants and healthcare workers will provide data on intervention feasibility and acceptability. Secondary clinical outcome measurements will be assessed at 3 and 6\u2009months and will include: weight, fasting plasma glucose, lipid profile, HbA1c<\/jats:sub> level; and the Brief Psychiatric Rating Scale.<\/jats:p>\n <\/jats:sec>\n Discussion<\/jats:title>\n This study should provide evidence of the potential benefits of liraglutide (maximum dosage 3.0\u2009mg daily) on body weight and metabolic variables in people with schizophrenia, schizoaffective disorder and first-episode psychosis. It will also address the feasibility and acceptability of the use of liraglutide in mental health settings. This will inform the design of a longer outcome study that will be needed to determine whether any weight loss can be maintained in the long term.<\/jats:p>\n <\/jats:sec>\n Trial registration<\/jats:title>\n Universal Trial Number (UTN), ID: U1111-1203-0068<\/jats:ext-link>. Registered on on 2\/10\/2017.<\/jats:p>\n European Clinical Trials Database (EudraCT), ID: 2017-004064-35<\/jats:ext-link>. Registered on 3\/10\/2017.<\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13063-019-3689-5","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T17:02:57Z","timestamp":1574269377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-1459","authenticated-orcid":false,"given":"Clare Alexandra","family":"Whicher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermione Clare","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Phiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanaya","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Barnard-Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Reidy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerensa","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Asher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Peveler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Ian Gregory","family":"Holt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"3","key":"3689_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0920-9964(01)00256-0","volume":"55","author":"P Homel","year":"2002","unstructured":"Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia. Schizophr Res. 2002;55(3):277\u201384.","journal-title":"Schizophr Res."},{"issue":"11","key":"3689_CR2","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1001\/archpsyc.1996.01830110060007","volume":"53","author":"KS Kendler","year":"1996","unstructured":"Kendler KS, Gallagher TJ, Abelson JM. The National Comorbidity Survey: lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. Arch Gen Psychiatry. 1996;53(11):1022\u201331.","journal-title":"Arch Gen Psychiatry"},{"key":"3689_CR3","unstructured":"Schizophrenia, in Problems and Disorders. Royal College of Psychiatry; 2015. http:\/\/www.rcpsych.ac.uk\/healthadvice\/problemsdisorders\/schizophrenia.aspx. Accessed Sept 2018."},{"issue":"2","key":"3689_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","volume":"196","author":"S Brown","year":"2010","unstructured":"Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2):116\u201321.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"3689_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","volume":"11","author":"RIG Holt","year":"2009","unstructured":"Holt RIG, Peveler R. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab. 2009;11(7):665\u201379.","journal-title":"Diabetes Obes Metab"},{"key":"3689_CR6","doi-asserted-by":"crossref","unstructured":"Kahn PRS. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform isorder: an open randomised clinical trial. Lancet. 2008;371:1085\u201397.","DOI":"10.1016\/S0140-6736(08)60486-9"},{"issue":"3","key":"3689_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","volume":"25","author":"BJ Kinon","year":"2005","unstructured":"Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3):255\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"7161","key":"3689_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/bmj.317.7161.784","volume":"317","author":"R McCreadie","year":"1998","unstructured":"McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ. 1998;317(7161):784\u20135.","journal-title":"BMJ."},{"key":"3689_CR9","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1017\/jns.2015.18","volume":"4","author":"K Williamson","year":"2015","unstructured":"Williamson K, Kilner K, Clibbens N. A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population. J Nutr Sci. 2015;4:e28.","journal-title":"J Nutr Sci."},{"issue":"10","key":"3689_CR10","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1038\/sj.npp.1301051","volume":"31","author":"I Elman","year":"2006","unstructured":"Elman I, Borsook D, Lukas S. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology. 2006;31(10):2091\u2013120.","journal-title":"Neuropsychopharmacology."},{"issue":"12","key":"3689_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.4088\/JCP.13m08642","volume":"74","author":"L Citrome","year":"2013","unstructured":"Citrome L, et al. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J Clin Psychiatry. 2013;74(12):1199\u2013206.","journal-title":"J Clin Psychiatry."},{"issue":"10","key":"3689_CR12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.2337\/dc13-0560","volume":"36","author":"K Barnard","year":"2013","unstructured":"Barnard K, Peveler R, Holt RIG. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation. Diabetes Care. 2013;36(10):3337\u201345.","journal-title":"Diabetes Care."},{"issue":"6","key":"3689_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1467-789X.2007.00393.x","volume":"8","author":"AS Poobalan","year":"2007","unstructured":"Poobalan AS, et al. Long-term weight loss effects on all cause mortality in overweight\/obese populations. J Obes Rev. 2007;8(6):503\u201313.","journal-title":"J Obes Rev."},{"key":"3689_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.schres.2012.03.017","volume":"140","author":"J Caemmerer","year":"2012","unstructured":"Caemmerer J, Correll CU. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res. 2012;140:159\u201368.","journal-title":"Schizophr Res."},{"key":"3689_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.genhosppsych.2017.04.003","volume":"47","author":"JA Naslund","year":"2017","unstructured":"Naslund JA, Whiteman KL, McHugo GJ. Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2017;47:83\u2013102.","journal-title":"Gen Hosp Psychiatry."},{"issue":"2","key":"3689_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/wps.20318","volume":"15","author":"H Speyer","year":"2016","unstructured":"Speyer H, Christian Brix N\u00f8rgaard H, Birk M, Karlsen M, Storch Jakobsen A, Pedersen K, et al. The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. World Psychiatry. 2016;15(2):155\u201365.","journal-title":"World Psychiatry."},{"key":"3689_CR17","doi-asserted-by":"crossref","unstructured":"Holt RIG, Gossage-Worrall R, Hind D, Bradburn MJ, McCrone P, Morris T, Edwardson C, Barnard K, Carey ME, Davies MJ, Dickens CM, Doherty Y, Etherington A, French P, Gaughran F, Greenwood KE, Kalidindi S, Khunti K, Laugharne R, Pendlebury J, Rathod S, Saxon D, Shiers D, Siddiqi N, Swaby EA, Waller G, Wright S. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry. 2019;214(2)63\u201373.","DOI":"10.1192\/bjp.2018.167"},{"issue":"6","key":"3689_CR18","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","volume":"40","author":"Y Mizuno","year":"2014","unstructured":"Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40(6):1385\u2013403.","journal-title":"Schizophr Bull."},{"issue":"10","key":"3689_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/sj.ijo.0803631","volume":"31","author":"L Citrome","year":"2007","unstructured":"Citrome L, Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31(10):1567\u201370.","journal-title":"Int J Obes"},{"issue":"2","key":"3689_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/dom.12795","volume":"19","author":"PL Ish\u00f8y","year":"2017","unstructured":"Ish\u00f8y PL, et al. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(2):162\u201371.","journal-title":"Diabetes Obes Metab."},{"key":"3689_CR21","doi-asserted-by":"crossref","unstructured":"Siskind DJ, et al. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab. 2018;20(4):1050\u20135.","DOI":"10.1111\/dom.13167"},{"issue":"7","key":"3689_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen JR, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(7):719\u201328.","journal-title":"JAMA Psychiatry"},{"key":"3689_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"3689_CR24","first-page":"301","volume":"65","author":"J Sim","year":"2012","unstructured":"Sim J. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficacy. J Clin Endocrinol. 2012;65(3):301\u20138.","journal-title":"J Clin Endocrinol."},{"issue":"3","key":"3689_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","volume":"25","author":"AL Whitehead","year":"2016","unstructured":"Whitehead AL, Julious SA, Cooper C, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057\u201373.","journal-title":"Stat Methods Med Res."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3689-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:21:29Z","timestamp":1605745289000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3689"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3689-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"South Central \u2013 Hampshire B Research Ethics Committee (REC) approved the study on 17 April 2018 with REC reference: \/SC\/0085. Only those who agree to provide written informed consent will be included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CAW, HCP, PP, SR and KT are employees of the Southern Health NHS Foundation Trust.HCP received fees for lecturing, consultancy work and attendance at conferences from Novo Nordisk.SR received fees for speaking at conferences from Janssen, Lundbeck and Otsuka.KBK received fees for advisory board participation, consultancy work and attendance at conferences from the following: Sanofi, Roche Diabetes Care, Lifescan, Novo Nordisk, Silvercloud, and Senseonics.RIGH received fees for lecturing, consultancy work and attendance at conferences from the following: Boehringer Ingelheim, Eli Lilly, Janssen, Lundbeck, Novo Nordisk, Novartis, Otsuka, Sanofi, Sunovion, Takeda, and MSD.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"633"}}